DK2807188T3 - Humaniserede antistoffer, der genkender alpha-synuclein - Google Patents
Humaniserede antistoffer, der genkender alpha-synuclein Download PDFInfo
- Publication number
- DK2807188T3 DK2807188T3 DK13740871.2T DK13740871T DK2807188T3 DK 2807188 T3 DK2807188 T3 DK 2807188T3 DK 13740871 T DK13740871 T DK 13740871T DK 2807188 T3 DK2807188 T3 DK 2807188T3
- Authority
- DK
- Denmark
- Prior art keywords
- humanized antibodies
- antibodies recognizing
- alpha synuclein
- recognizing alpha
- synuclein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Radiology & Medical Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591835P | 2012-01-27 | 2012-01-27 | |
| US201261711207P | 2012-10-08 | 2012-10-08 | |
| PCT/US2013/023307 WO2013112945A1 (en) | 2012-01-27 | 2013-01-25 | Humanized antibodies that recognize alpha-synuclein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2807188T3 true DK2807188T3 (da) | 2019-10-07 |
Family
ID=48873980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13740871.2T DK2807188T3 (da) | 2012-01-27 | 2013-01-25 | Humaniserede antistoffer, der genkender alpha-synuclein |
Country Status (22)
| Country | Link |
|---|---|
| US (7) | US8790644B2 (enExample) |
| EP (1) | EP2807188B1 (enExample) |
| JP (2) | JP6342333B2 (enExample) |
| KR (2) | KR102246217B1 (enExample) |
| CN (2) | CN104619724B (enExample) |
| AU (1) | AU2013211874B2 (enExample) |
| BR (1) | BR112014018561A8 (enExample) |
| CA (1) | CA2863953A1 (enExample) |
| CL (1) | CL2014001984A1 (enExample) |
| DK (1) | DK2807188T3 (enExample) |
| ES (1) | ES2749457T3 (enExample) |
| IL (2) | IL233829B (enExample) |
| IN (1) | IN2014DN07149A (enExample) |
| MX (2) | MX360778B (enExample) |
| MY (1) | MY171140A (enExample) |
| NZ (1) | NZ629296A (enExample) |
| PH (1) | PH12014501685A1 (enExample) |
| RU (1) | RU2642262C2 (enExample) |
| SG (1) | SG11201404321YA (enExample) |
| UA (1) | UA115439C2 (enExample) |
| WO (1) | WO2013112945A1 (enExample) |
| ZA (1) | ZA201406227B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2771031B1 (en) | 2011-10-28 | 2018-04-18 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| EP2807188B1 (en) | 2012-01-27 | 2019-09-11 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| KR102813816B1 (ko) * | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| LT3071597T (lt) * | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| CN106568969B (zh) * | 2016-10-19 | 2017-09-26 | 首都医科大学 | 一种丝氨酸129位磷酸化alpha‑突触核蛋白聚集体的ELISA检测方法 |
| EP3548074A4 (en) * | 2016-12-02 | 2020-07-01 | Prothena Biosciences Limited | INFRARED ASSAY DETECTING SECONDARY ALPHA-SYNUCLEIN STRUCTURE PROFILES |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| JP7136790B2 (ja) * | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| EP3406632A1 (en) | 2017-05-23 | 2018-11-28 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Ligands binding to prion protein for use in the treatment of synucleinopathies |
| EP3661961A4 (en) * | 2017-08-02 | 2021-04-14 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| WO2019195770A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| EP3833435B1 (en) | 2018-08-09 | 2025-09-24 | F. Hoffmann-La Roche AG | Determination of parkinson's disease |
| BR112021006123A2 (pt) * | 2018-10-19 | 2021-07-20 | Janssen Vaccines & Prevention B.V. | anticorpos anti-sinucleína |
| AU2020358854B2 (en) * | 2019-10-03 | 2026-08-13 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| MX2022013173A (es) | 2020-04-24 | 2022-11-30 | Hoffmann La Roche | Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados. |
| AU2021310926A1 (en) * | 2020-07-23 | 2023-03-23 | Othair Prothena Limited | Anti-abeta antibodies |
| CN117858721A (zh) * | 2021-05-12 | 2024-04-09 | Abl生物公司 | 用于治疗α-突触核蛋白病的抗体 |
| CN113912714B (zh) * | 2021-12-15 | 2022-02-22 | 北京凯祥弘康生物科技有限公司 | 特异性结合α-突触核蛋白的抗体及其应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| JP2000510813A (ja) | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Ｉｌ−１２用処方 |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| MY128897A (en) | 1999-02-05 | 2007-02-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| AU2003299498A1 (en) * | 2002-05-13 | 2004-05-25 | Alexion Pharmaceuticals, Inc. | Humanized antibodies against the venezuelan equine encephalitis virus |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| DE50308030D1 (de) | 2002-11-29 | 2007-10-04 | Boehringer Ingelheim Pharma | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| JP2007512846A (ja) * | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1820022B1 (en) | 2004-11-10 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| US7930064B2 (en) * | 2004-11-19 | 2011-04-19 | Parata Systems, Llc | Automated drug discrimination during dispensing |
| CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| RU2498999C2 (ru) | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| HUE033325T2 (en) * | 2007-01-05 | 2017-11-28 | Univ Zuerich | Anti-beta-amyloid binder antibodies and their use |
| PL2583978T3 (pl) | 2007-02-23 | 2016-07-29 | Prothena Biosciences Ltd Co | Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych |
| CN103396489A (zh) | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| EP2522730A1 (en) | 2007-03-02 | 2012-11-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
| PL2132230T3 (pl) | 2007-03-22 | 2014-09-30 | Genentech Inc | Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną |
| CA2681743A1 (en) | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| WO2009080541A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Antibody formulation |
| WO2009086539A2 (en) | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
| AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| ES2709048T3 (es) | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
| WO2009141239A1 (en) | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
| DE102008048129A1 (de) | 2008-09-20 | 2010-04-22 | Lfk-Lenkflugkörpersysteme Gmbh | Flugkörper mit zumindest einem Bremsfallschirm sowie Befestigungsvorrichtung zur Befestigung eines Bremsfallschirms an einem Flugkörper |
| HRP20150831T1 (hr) | 2008-12-19 | 2015-10-09 | Biogen International Neuroscience Gmbh | Humana anti-alfa- sinuklein auto-protutijela |
| AU2010281403B2 (en) | 2009-07-28 | 2016-03-10 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Gaucher disease |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US20130116413A1 (en) | 2009-12-29 | 2013-05-09 | Dr. Reddy's Laboratories, Inc. | Purification of proteins |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2560994B1 (en) * | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| CA3220104A1 (en) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| CN103079644B (zh) * | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| EP3345925A3 (en) * | 2010-07-15 | 2018-09-26 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
| BR112013008738B1 (pt) | 2010-10-11 | 2017-12-19 | Abbvie Bahamas Ltd. | Method for purification of a protein |
| US20140050733A1 (en) | 2011-02-07 | 2014-02-20 | Dale B. Schenk | Apoe immunotherapy |
| WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
| AU2012272815B2 (en) | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
| RU2013155695A (ru) | 2011-06-30 | 2015-08-10 | Дженентек, Инк. | Препараты антител против с-мет |
| EP2771031B1 (en) | 2011-10-28 | 2018-04-18 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| AU2012332767C1 (en) | 2011-10-31 | 2017-02-02 | Genentech, Inc. | Antibody formulations |
| EP2807188B1 (en) | 2012-01-27 | 2019-09-11 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| MX367126B (es) | 2012-08-29 | 2019-08-06 | Hoffmann La Roche | Transporte para atravesar la barrera hematoencefálica. |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2013
- 2013-01-25 EP EP13740871.2A patent/EP2807188B1/en active Active
- 2013-01-25 JP JP2014554890A patent/JP6342333B2/ja not_active Expired - Fee Related
- 2013-01-25 SG SG11201404321YA patent/SG11201404321YA/en unknown
- 2013-01-25 DK DK13740871.2T patent/DK2807188T3/da active
- 2013-01-25 WO PCT/US2013/023307 patent/WO2013112945A1/en not_active Ceased
- 2013-01-25 AU AU2013211874A patent/AU2013211874B2/en not_active Ceased
- 2013-01-25 US US13/750,983 patent/US8790644B2/en not_active Expired - Fee Related
- 2013-01-25 CA CA2863953A patent/CA2863953A1/en not_active Abandoned
- 2013-01-25 MX MX2014008952A patent/MX360778B/es active IP Right Grant
- 2013-01-25 IN IN7149DEN2014 patent/IN2014DN07149A/en unknown
- 2013-01-25 CN CN201380007018.8A patent/CN104619724B/zh not_active Expired - Fee Related
- 2013-01-25 RU RU2014134747A patent/RU2642262C2/ru active
- 2013-01-25 BR BR112014018561A patent/BR112014018561A8/pt active Search and Examination
- 2013-01-25 CN CN201810297949.0A patent/CN108517010A/zh active Pending
- 2013-01-25 KR KR1020207006200A patent/KR102246217B1/ko not_active Expired - Fee Related
- 2013-01-25 MY MYPI2014002199A patent/MY171140A/en unknown
- 2013-01-25 KR KR1020147024060A patent/KR102086061B1/ko not_active Expired - Fee Related
- 2013-01-25 UA UAA201409460A patent/UA115439C2/uk unknown
- 2013-01-25 ES ES13740871T patent/ES2749457T3/es active Active
- 2013-01-25 NZ NZ629296A patent/NZ629296A/en not_active IP Right Cessation
-
2014
- 2014-07-24 US US14/340,342 patent/US9234031B2/en not_active Expired - Fee Related
- 2014-07-24 US US14/340,355 patent/US9217030B2/en not_active Expired - Fee Related
- 2014-07-24 MX MX2018014044A patent/MX2018014044A/es unknown
- 2014-07-24 PH PH12014501685A patent/PH12014501685A1/en unknown
- 2014-07-25 CL CL2014001984A patent/CL2014001984A1/es unknown
- 2014-07-27 IL IL233829A patent/IL233829B/en active IP Right Grant
- 2014-08-25 ZA ZA2014/06227A patent/ZA201406227B/en unknown
-
2015
- 2015-11-10 US US14/937,792 patent/US9670273B2/en not_active Expired - Fee Related
-
2017
- 2017-05-04 US US15/587,255 patent/US10118960B2/en not_active Expired - Fee Related
-
2018
- 2018-05-16 JP JP2018094968A patent/JP6807893B2/ja not_active Expired - Fee Related
- 2018-09-27 US US16/144,923 patent/US10597441B2/en not_active Expired - Fee Related
-
2020
- 2020-02-19 US US16/795,479 patent/US10875909B2/en not_active Expired - Fee Related
-
2021
- 2021-03-22 IL IL281731A patent/IL281731A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2024011I2 (el) | Αντισωματα anti-fcrn | |
| NO2023024I1 (no) | Spesolimab, an ant-IL-36R antibody | |
| DK3378535T5 (da) | Humanserede antistoffer, der genkender alpha-synuklein | |
| SG11201502662QA (en) | Antibodies recognizing alpha-synuclein | |
| DK2934584T3 (da) | Anti-gdf15-antistoffer | |
| HRP20181646T1 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
| DK2847231T3 (da) | Multispecifikke monoklonale antistoffer | |
| DK3083694T5 (da) | Caniniserede, murine anti-canin-pd-1-antistoffer | |
| LT2906597T (lt) | Antikūnai, atpažįstantys beta amiloidą | |
| BR112014024769A2 (pt) | anticorpo humanizado tau | |
| DK3156416T3 (da) | Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer | |
| DK2817333T3 (da) | Bispecifikke, asymmetriske igg4-antistoffer | |
| PL3088421T3 (pl) | Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej | |
| DK3653645T3 (da) | Monoklonal interleukin-31-antistof | |
| BR112014025037A2 (pt) | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente | |
| HRP20181874T1 (hr) | Anti-cxcr3 protutijela | |
| EP2807188A4 (en) | HUMANIZED ANTIBODIES THAT RECOGNIZE ALPHA-SYNUCLEIN | |
| DK3431504T3 (da) | Antiphospholipase d4-antistof | |
| DK2931748T3 (da) | Bmp-6-antistoffer | |
| DK3521315T3 (da) | Anti-transglutaminase-2-antistoffer | |
| DK2828292T3 (da) | Jcv-neutraliserende antistoffer | |
| DK2935330T3 (da) | Anti-notch3-antistoffer | |
| LT2814843T (lt) | ŽMOGAUS MONOKLONINIAI ANTIKŪNAI, NEUTRALIZUOJANTYS IL-1ß | |
| CO6841994A2 (es) | Anticuerpos |